

StageZero on revenues being generated via testing operations, partners and a status report on the Aristotle test

written by InvestorNews | January 21, 2021

In a recent InvestorIntel interview, Tracy Weslosky speaks with James Howard-Tripp, Chairman and CEO of [StageZero Life Sciences Ltd.](#) (TSX: SZLS) about an update on StageZero's Aristotle test. This test, which can simultaneously screen for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer, was one of numerous discussions they had in this interview.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), James went on to say that StageZero is on track and continues to advance towards the launch of its Aristotle® test. He further said that StageZero has generated revenues with its COVID-19 testing operations which continues to grow every quarter. "We think COVID revenue is going to continue for a while...it should get eclipsed by Aristotle® when Aristotle® comes forward," He said. "We are two and half time bigger now than we were in March last year."

Speaking on StageZero's Virtual COVID-19 PCR Testing Program James said, "We have partnered with [Ichor](#) and Air Canada to equip the passengers, when they leave, with kits to allow them get tested while they were away and get back again."

To watch the complete interview, [click here](#)

About StageZero Life Sciences, Ltd.

StageZero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The Company operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. A specialist in PCR testing for the early identification of Cancer through blood, the Company is uniquely positioned to provide both COVID PCR testing (swab) and blood test analysis (Antibody testing). Our full service, telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups. As we provide COVID-19 test during this Pandemic, we continue making progress with our mission to eradicate late stage cancers through early detection. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer.

To know more about StageZero Life Sciences Ltd., [click here](#)

Disclaimer: StageZero Life Sciences Ltd. is an advertorial member of InvestorIntel Corp.